Solid Biosciences to Present at Upcoming Scientific and Patient Advocacy Conferences

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) announced its participation in two significant conferences focusing on Duchenne muscular dystrophy therapies. At the PPMD 2022 Annual Conference from June 23-26 in Scottsdale, AZ, Chief Scientific Officer Carl Morris will discuss gene therapy approaches on June 24 at 11:30 a.m. EDT. Subsequently, at the ICNMD 2022 in Brussels from July 5-9, Perry Shieh will present selected abstracts on July 7 at 10:30 a.m. ET. Solid Biosciences is dedicated to developing innovative treatments like SGT-001 and SGT-003 to address Duchenne at its genetic source.

CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate in the following upcoming scientific and patient advocacy conferences:

PPMD 2022 Annual Conference – June 23-26, 2022, Scottsdale, AZ
Carl Morris, Ph.D., Chief Scientific Officer at Solid Biosciences, will participate in the Gene Therapy Approaches to Replace or Restore Dystrophin session on Friday, June 24, at 11:30 a.m. EDT / 8:30 a.m. MST.

Event and registration information is available at:
https://www.parentprojectmd.org/events/ppmds-2022-annual-conference/

ICNMD 2022 | 17^th International Congress on Neuromuscular Diseases – July 5-9, 2022, Brussels, BE
Perry Shieh, M.D., Ph. D. Professor of Neurology and Pediatrics at the University of California, Los Angeles, and an IGNITE DMD investigator, will participate in the PS03: Selected Abstracts for Oral Presentation session on Thursday, July 7, at 10:30 a.m. ET / 4:30 p.m. CEST.

Event and registration information is available at: https://icnmd.org/registration2022/

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001, as well as our recently announced next-generation gene therapy candidate, SGT-003. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Caitlin Lowie
Solid Biosciences
607-423-3219
CLowie@solidbio.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com

FAQ

What conferences is Solid Biosciences participating in June 2022?

Solid Biosciences is participating in the PPMD 2022 Annual Conference and the ICNMD 2022.

Who will represent Solid Biosciences at the PPMD 2022 Annual Conference?

Carl Morris, Chief Scientific Officer, will represent Solid Biosciences at the PPMD 2022 Annual Conference.

When is the PPMD 2022 Annual Conference?

The PPMD 2022 Annual Conference takes place from June 23-26, 2022.

What is the date and location of the ICNMD 2022?

The ICNMD 2022 is scheduled for July 5-9, 2022, in Brussels, Belgium.

What session will Carl Morris speak at during the PPMD 2022?

Carl Morris will speak at the Gene Therapy Approaches to Replace or Restore Dystrophin session on June 24 at 11:30 a.m. EDT.

What is the focus of Solid Biosciences' research?

Solid Biosciences focuses on developing therapies for Duchenne muscular dystrophy, specifically targeting the genetic mutation causing the disease.